80943-41-5

Basic information

• Product Name: a-D-Glucopyranoside, methyl4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-
• Synonyms: a-D-Glucopyranoside, methyl4,6-dideoxy-4-[[4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-,[1S-(1a,4a,5b,6a)]-; (S)-Acarviosin; Acarviosin; Acarviosine
• CAS NO: 80943-41-5
• Molecular Formula: C14H25 N O8
• Molecular Weight: 335.354
• Mol File: 80943-41-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: a-D-Glucopyranoside, methyl4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: a-D-Glucopyranoside, methyl4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-(80943-41-5)
• EPA Substance Registry System: a-D-Glucopyranoside, methyl4,6-dideoxy-4-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-2-cyclohexen-1-yl]amino]-(80943-41-5)

Safety Data

• Hazardous Substances Data: 80943-41-5(Hazardous Substances Data)

Upstream product

• 56180-94-0 acarbose 
• 142200-26-8 Methyl-4-<(1S)-(1,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2-cyclohexen-1-yl>amino-D-glucopyranosid 
• 24578-12-9 Methyl 3,4-anhydro-α-D-galactopyranoside 
• 90025-02-8 (1S,2S,3S,4R)-1-amino-5-(hydroxymethyl)-2,3:4,6-di-O-isopropylidene-5-cyclohexene-2,3,4-triol 
• 131922-34-4 4',7':5',6'-Di-O-isopropylidene derivative of methyl 4-deoxy-6-O-p-tolylsulfonyl-4-<(1S)-(1,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2-cyclohexenyl>amino-α-D-glucopyranoside 
• 131922-33-3 4',7':5',6'-Di-O-isopropylidene derivative of methyl 4-deoxy-4-<(1S)-(1,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2-cyclohexenyl>amino-α-D-glucopyranoside 
• 38231-86-6 valienamine 
• 89859-43-8 methyl 2,3-O-cyclohexylidene-6-deoxy-α-D-xylo-hexopyranosid-4-ulose 

Relevant articles and documents

Synthesis and study of the pancreatic α-amylase inhibitory activity of methyl acarviosin and its derivatives

Pancreatic α-amylase is a target for type 2 diabetes mellitus treatment. However, small molecule inhibitors of α-amylase are currently scarce. In the course of developing small molecule α-amylase inhibitors, we designed and synthesized conjugates of gluco

Synthesis and α-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents

-